Front. Oncol., 02 April 2014 | doi: 10.3389/fonc.2014.00070

Control of the immune response by pro-angiogenic factors

imageThibault Voron1, imageElie Marcheteau1, imageSimon Pernot1,2, imageOrianne Colussi1,2, imageEric Tartour1,3, imageJulien Taieb1,2 and imageMagali Terme1*
  • 1INSERM U970, PARCC (Paris Cardiovascular Research Center), Université Paris-Descartes, Sorbonne Paris Cité, Paris, France
  • 2Service d’Hépatogastroentérologie et d’Oncologie Digestive, Hôpital Européen Georges Pompidou, Paris, France
  • 3Service d’Immunologie Biologique, Hôpital Européen Georges Pompidou, Paris, France

The progressive conversion of normal cells into cancer cells is characterized by the acquisition of eight hallmarks. Among these criteria, the capability of the cancer cell to avoid the immune destruction has been noted. Thus, tumors develop mechanisms to become invisible to the immune system, such as the induction of immunosuppressive cells, which are able to inhibit the development of an efficient immune response. Molecules produced in the tumor microenvironment are involved in the occurrence of an immunosuppressive microenvironment. Recently, it has been shown that vascular endothelial growth factor A (VEGF-A) exhibits immunosuppressive properties in addition to its pro-angiogenic activities. VEGF-A can induce the accumulation of immature dendritic cells, myeloid-derived suppressor cells, regulatory T cells, and inhibit the migration of T lymphocytes to the tumor. Other pro-angiogenic factors such as placental growth factor (PlGF) could also participate in tumor-induced immunosuppression, but only few works have been performed on this point. Here, we review the impact of pro-angiogenic factors (especially VEGF-A) on immune cells. Anti-angiogenic molecules, which target VEGF-A/VEGFR axis, have been developed in the last decades and are commonly used to treat cancer patients. These drugs have anti-angiogenic properties but can also counteract the tumor-induced immunosuppression. Based on these immunomodulatory properties, anti-angiogenic molecules could be efficiently associated with immunotherapeutic strategies in preclinical models. These combinations are currently under investigation in cancer patients.

Keywords: pro-angiogenic factors, VEGF-A, PlGF, tumor, immunosuppression, regulatory T cells, MDSC, immunotherapy

Citation: Voron T, Marcheteau E, Pernot S, Colussi O, Tartour E, Taieb J and Terme M (2014) Control of the immune response by pro-angiogenic factors. Front. Oncol. 4:70. doi: 10.3389/fonc.2014.00070

Received: 30 January 2014; Accepted: 20 March 2014;
Published online: 02 April 2014.

Edited by:

Christian Stockmann, Institut National de la Santé et de la Recherche Médicale, France

Reviewed by:

Salem Chouaib, Institut Gustave Roussy, France
Graham Robert Leggatt, University of Queensland, Australia
Carlos Alfaro, Clínica Universidad de Navarra, Spain

Copyright: © 2014 Voron, Marcheteau, Pernot, Colussi, Tartour, Taieb and Terme. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Magali Terme, INSERM U970, PARCC (Paris Cardiovascular Research Center), Université Paris-Descartes, Sorbonne Paris Cité, 56 rue Leblanc, Paris 75015, France e-mail:

Back to top